OTC:ODYY
Odyssey Health, Inc.
A pre-revenue biopharmaceutical firm developing next-generation therapies for high-value indications like oncology and autoimmune diseases.
Key Metrics
Investment Thesis
Bull Case
An early-stage investor might buy ODYY if they believe the company can secure substantial new capital or asset acquisition deals given its zero current liabilities and paid-in capital of $55.7M. The potential for a blockbuster drug launch in oncology could transform the company's valuation from a penny stock to a mid-cap biotech overnight.
Bear Case
The stock is fundamentally flawed with a shareholders' equity deficit of -$7.0M and zero revenue, making it a speculative bet on future funding rather than current earnings power. The worsening profit trends and lack of commercial products expose investors to a high probability of dilution or liquidation before any value creation occurs.
About Odyssey Health, Inc.
Odyssey Health, Inc. (ODYY) is a biopharmaceutical entity focused on the discovery and development of novel therapeutic products, primarily targeting autoimmune disorders and oncology markets. The company currently operates with minimal current revenue, relying heavily on paid-in capital to fund research initiatives while managing significant operational losses.
Analysis
Management Discussion
Odyssey Health has intensified its financial burn, with net income deteriorating from a -$5.9M loss in 2023 to a -$1.7M loss in 2025, driven by $1.0M in general and administrative expenses against zero revenue. Despite generating $294k in financing cash flow and $69k in investing cash flow, the company's operating cash flow turned significantly negative at -$347k, leading to a net change in cash of only $16k despite ending with $19k in cash.
Industry Overview
The biotechnology industry is characterized by high risk and long development cycles where companies often operate at significant losses while investing in R&D before achieving commercialization. Success depends on securing regulatory approval for novel therapies, which carries a binary outcome of either massive market capture or total asset write-downs.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $0 | — | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | — | $0 |
| Operating Expenses | $5.3M | — | $1.0M |
| Operating Income | $-5.3M | $14.3M | $-1.0M |
| R&D | — | — | $0 |
| G&A | $2.1M | $1.5M | $1.0M |
| Stock-Based Comp | — | $577.8K | $108.4K |
| D&A | — | $1.5K | — |
| Depreciation | $0 | — | — |
| Amortization | — | $1.5K | — |
| Other OpEx | $3.2M | — | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Expense | $614.1K | — | — |
| Pre-Tax Income | $-5.3M | $14.3M | $-1.0M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-5.3M | $14.3M | $-1.0M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-5.9M | $-842.3K | $-1.7M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-5.9M | $-842.3K | $-1.7M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $405.9K | $56.9K | $49.7K |
| Cash & Equivalents | $36.9K | — | — |
| Prepaid Expenses | $92.5K | $31.9K | $30.6K |
| Other Current Assets | $276.6K | $25.0K | $19.1K |
| Long-Term Assets | $49.9K | $529.2K | $0 |
| Total Assets | $455.8K | $586.1K | $49.7K |
| Current Liabilities | $6.6M | $5.9M | $7.0M |
| Accounts Payable | $1.8M | $1.3M | $1.6M |
| Other Current Liab | $4.8M | $4.6M | $5.4M |
| Long-Term Liabilities | $0 | $0 | $0 |
| Total Liabilities | $6.6M | $5.9M | $7.0M |
| Shareholders' Equity | $-6.2M | $-5.3M | $-7.0M |
| Paid-In Capital | $53.9M | $55.6M | $55.7M |
| Retained Earnings | $-60.1M | $-61.0M | $-62.7M |
| Total L&E | $455.8K | $586.1K | $49.7K |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $-5.9M | $-842.3K | $-1.7M |
| Non-Cash Adjustments | — | $-258.8K | $655.4K |
| Working Capital Changes | — | $-114.1K | $739.9K |
| Cash from Operations | — | $-1.2M | $-347.4K |
| Cash from Investing | — | $1.0M | $69.8K |
| Cash from Financing | — | $180.7K | $294.3K |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | — | $-34.5K | $16.7K |
| Beginning Cash | — | $36.9K | $2.4K |
| Ending Cash | $36.9K | $2.4K | $19.1K |
Frequently Asked Questions
How does Odyssey Health, Inc. make money?
The company's financial structure suggests a focus on R&D-intensive segments such as oncology and autoimmune disease development, with current operations limited to general administrative expenses and share-based compensation rather than traditional product sales.
What are the main risks for ODYY?
Complete lack of revenue and zero cost of goods sold indicates no established commercial product base yet; severe negative net profit trends worsening from 2023 to 2025; substantial retained earnings deficit of $62.7M creating a high risk of insolvency if financing dries up; heavy reliance on financing cash flows to offset massive operating burn.
What is ODYY's competitive advantage?
Access to proprietary intellectual property in high-value therapeutic areas; utilization of non-cash adjustments like share-based compensation to conserve cash flow for R&D; potential for significant value accretion upon successful clinical trial milestones or licensing deals.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.